Astellas Pharma Inc. (TYO:4503)
Japan · Delayed Price · Currency is JPY 2,236.50
+23.50 (1.06%)
At close: Jan 9, 2026
Astellas Pharma Employees
Astellas Pharma had 13,643 employees as of March 31, 2025. The number of employees decreased by 1,111 or -7.53% compared to the previous year.
Employees
13,643
Change (1Y)
-1,111
Growth (1Y)
-7.53%
Revenue / Employee
147.09M JPY
Profits / Employee
9.15M JPY
Market Cap
3.96T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 13,643 | -1,111 | -7.53% |
| Mar 31, 2024 | 14,754 | 270 | 1.86% |
| Mar 31, 2023 | 14,484 | -38 | -0.26% |
| Mar 31, 2022 | 14,522 | -933 | -6.04% |
| Mar 31, 2021 | 15,455 | -428 | -2.69% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| HOYA Corporation | 37,909 |
| Otsuka Holdings | 35,338 |
| Olympus | 29,297 |
| Daiichi Sankyo Company | 19,765 |
| M3, Inc. | 15,360 |
| Eisai | 10,917 |
| Kyowa Kirin | 5,669 |
Astellas Pharma News
- 2 days ago - Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 22 days ago - Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer - Nasdaq
- 23 days ago - Why Is Monte Rosa Stock Trading Higher Today? - Benzinga
- 4 weeks ago - Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines - GlobeNewsWire
- 4 weeks ago - Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium - PRNewsWire
- 5 weeks ago - Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting - PRNewsWire
- 5 weeks ago - EMA Validates Review Of Astellas' PADCEV And KEYTRUDA Combination In Bladder Cancer - Nasdaq
- 6 weeks ago - Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Nasdaq